Rotigotine
Overview
Rotigotine is a non-ergoline, dopamine agonist used in the treatment of Parkinson’s disease and restless legs syndrome. It functions as a transdermal patch to deliver continuous stimulation to dopamine receptors.
API suppliers (8)
Suppliers of Rotigotine evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
4 of 8 hold a GMP certificate on record in the EU or UK registers
- Sichuan Qingmu Pharmaceutical Co., Ltd.China1 active DMF
- WAVELENGTH ENTERPRISES LTDIsrael1 active DMF GMP on record
- INTERQUIM SAPeru1 active DMF GMP on record
- MATRIX PHARMACORP PRIVATE LTDIndia1 active DMF
- TAPI NL BVNetherlands1 active DMF
- Neuland Laboratories LimitedIndia1 active DMF
- SOLARA ACTIVE PHARMA SCIENCES LTDIndia1 active DMF GMP on record
- OLON SPAItaly GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Rotigotine expires 1 Mar 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Rotigotine? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.